Hart Roger J, Rombauts Luk, Norman Robert J
aSchool of Women's and Infants' Health, University of Western Australia, Perth bFertility Specialists of Western Australia, Bethesda Hospital, Claremont, Western Australia cWomen's Health, Monash Health dDepartment of Obstetrics and Gynaecology, Monash University, Clayton, Victoria eRobinson Institute, University of Adelaide, Fertility SA, Adelaide, South Australia, Australia.
Curr Opin Obstet Gynecol. 2017 Jun;29(3):119-125. doi: 10.1097/GCO.0000000000000360.
Growth hormone (GH) has been used as an adjunct in ovulation induction and IVF for 25 years, particularly as an adjunct to ovarian stimulation for women who had a previous poor response to stimulation in an IVF cycle. It does not have US Food and Drug Administration approval for this use. Unfortunately, due to the problems inherent with recruiting women who have undergone unsuccessful IVF treatment cycles and their inevitable low live birth rate per initiated cycle, many studies performed to date have been underpowered.
Previous meta-analyses of studies performed in populations of women with a poor response to ovarian stimulation, demonstrated an increase in the live birth rate for the use of GH. With the recent publication of three studies and the presentation of the Australian LIGHT study, we undertook an updated meta-analysis.
Meta-analysis demonstrated a benefit for the use of the adjunct GH, with a reduction in the duration of ovarian stimulation required for oocyte retrieval, the collection of a greater number of oocytes than placebo, and an improvement in many of the early clinical parameters; however, there was no evidence of an increased chance of a live birth for the use of GH.
生长激素（GH）作为促排卵和体外受精（IVF）的辅助药物已使用了25年，尤其用于对IVF周期中先前刺激反应不佳的女性的卵巢刺激辅助治疗。它未获得美国食品药品监督管理局对此用途的批准。不幸的是，由于招募经历过IVF治疗周期失败的女性存在固有问题，且每个启动周期的活产率必然较低，迄今为止进行的许多研究的样本量都不足。
先前对卵巢刺激反应不佳的女性群体进行的研究的荟萃分析表明，使用GH可提高活产率。随着最近三项研究的发表以及澳大利亚LIGHT研究的报告，我们进行了更新的荟萃分析。
荟萃分析表明使用辅助性GH有益，可减少获取卵母细胞所需的卵巢刺激时间，比使用安慰剂收集到更多的卵母细胞，并改善许多早期临床参数；然而，没有证据表明使用GH会增加活产的机会。
